Submission & Approval

Breakthrough Therapy Designation(BTD)

An FDA designation for drugs showing substantial improvement over existing treatments for serious conditions.

Usage Examples

The CAR-T therapy received Breakthrough Therapy Designation.
BTD enabled extensive FDA interaction during development.
The breakthrough designation was based on Phase 2 response rates.

What is BTD?

Breakthrough Therapy Designation (BTD) is an FDA program to expedite development and review of drugs that may demonstrate substantial improvement over available therapies for serious or life-threatening conditions.

To qualify, preliminary clinical evidence must show the drug may demonstrate substantial improvement on clinically significant endpoints compared to existing treatments. Benefits of BTD include intensive FDA guidance on efficient development, organizational commitment involving senior managers, and rolling review of the application.

BTD is distinct from other expedited programs (Fast Track, Accelerated Approval, Priority Review) though drugs may qualify for multiple designations. BTD does not change approval standards but aims to get promising drugs to patients faster.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDASIA SECTION 902.

FDAICHEMA

When This Matters

The CAR-T therapy received Breakthrough Therapy Designation.
BTD enabled extensive FDA interaction during development.
The breakthrough designation was based on Phase 2 response rates.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

FDASIA SECTION 902

Frequently Asked Questions

Benefits include intensive FDA guidance, organizational commitment from senior FDA managers, potential rolling review, and typically expedited development and review timelines.

BTD requires preliminary clinical evidence of substantial improvement, while Fast Track requires the drug to address an unmet need. BTD provides more intensive engagement including senior manager involvement.

No, BTD facilitates development but doesn't change approval standards or guarantee approval. However, BTD drugs often also receive Priority Review, which does expedite the review timeline.